NCT07124559 - A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

December 15, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

May 31, 2028

Conditions

Tuberculosis

Interventions

DRUG

Rifapentine

Dispersible Tablet administered orally

DRUG

Isoniazid

Dispersible Tablet administered orally

DRUG

Dolutegravir

Tablets and Tablets for oral suspension administered orally

Trial Locations (11)

10700

Siriraj Hospital, Mahidol University (Site ID: 5115), Bangkok

20200

Kenya Medical Research Institute, Walter Reed Project Clinical Research Center (Site ID: 5121), Kericho

57000

Chiangrai Prachanukroh Hospital (Site ID: 5116), Chiang Rai

Unknown

Gaborone (Site ID: 12701), Gaborone

Molepolole (Site ID: 12702), Gaborone

Baylor-Uganda (Site ID: 31798), Kampala

MU-JHU Care Limited (Site ID: 5126), Kampala

Harare Family Care (Site ID: 31890), Belgravia

Seke North (Site ID: 30306), Belgravia

St Mary's (Site ID: 30303), Chitungwiza

HT-6110

Les Centres GHESKIO (Site ID: 30022), Port-au-Prince

All Listed Sponsors

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH